Search

everythinglearnresearchcommunity

for

Search:↓

Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.

Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.

Certain gut bacteria may protect against alopecia areata, while others may increase the risk.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Higher antigliadin antibody levels are linked to alopecia areata severity.

No link between scalp patterns and alopecia severity in children, but more severe cases often had nail abnormalities.

PRP may help hair growth in alopecia areata without major side effects, but more research is needed.

Plant-based chemicals may help hair growth and prevent hair loss but need more research to compete with current treatments.

Combining OMP with cyclosporine can effectively treat severe alopecia areata in children.

Alopecia areata is a reversible, autoimmune-related hair loss that can have significant emotional impact and uncertain treatment effectiveness.

Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.

PRP more effective than minoxidil 5% for treating alopecia areata.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

People with alopecia areata often have lower levels of vitamin D, zinc, and folate, but more research is needed to understand if supplements can help treat it.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Effective management of children's hair loss involves accurate diagnosis, various treatments, and supportive care.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Accurate diagnosis is key for treating different kinds of hair loss, and immune response variations may affect the condition and treatment results.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Intralesional triamcinolone acetonide is effective for treating patchy hair loss, and dermoscopy helps detect treatment response and side effects early.

Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.

Men with common hair loss may have a higher risk of heart disease and diabetes, and should be checked for these conditions.